glp-1 receptor list agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 Agonists - Endocrinology Advisor

The ability of GAL to exert its stimulation of feeding responses may be due to its interactions with other peptide systems

Related Reading Semaglutide Genetics Weight Management Weight Management Semaglutide Tcf7L2 Rs7903146 Weight Management Semaglutide Pparg Rs1801282 Weight Management Semaglutide Fto Rs9939609 Pricing and availability current as of June 2026

Mild bloating or early satiety , likely related to delayed gastric emptying

While USADA has a team available to help answer your specific questions (contact info below), we also urge you to use GlobalDRO.com to search the prohibited status of your medications and ingredients